Compare · AZN vs DNTH
AZN vs DNTH
Side-by-side comparison of AstraZeneca PLC (AZN) and Dianthus Therapeutics Inc. (DNTH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and DNTH operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $263.10B, about 42.0x DNTH ($6.27B).
- DNTH has been more active in the news (16 items in the past 4 weeks vs 13 for AZN).
- AZN has more recent analyst coverage (25 ratings vs 14 for DNTH).
- Company
- AstraZeneca PLC
- Dianthus Therapeutics Inc.
- Price
- -
- -
- Market cap
- $263.10B
- $6.27B
- 1M return
- -
- +7.33%
- 1Y return
- -
- +360.46%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- 2018
- News (4w)
- 13
- 16
- Recent ratings
- 25
- 14
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Latest AZN
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
- ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- TAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO
- Enhertu® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival as First-Line Treatment of Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial
- SVP, Group Controller Sharma Mani was granted 2 units of Ordinary Shares, increasing direct ownership by 0.01% to 19,267 units (SEC Form 4)
Latest DNTH
- Director Read Simon sold $326,554 worth of shares (2,778 units at $117.55) as part of a pre-agreed trading plan and exercised 2,778 shares at a strike of $18.36 (SEC Form 4)
- SVP, General Counsel and Sec. Veness Adam M exercised 15,000 shares at a strike of $18.17 (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Dianthus Therapeutics Inc.
- Director Mcgeorge Anne exercised 7,750 shares at a strike of $12.52 and sold $844,822 worth of shares (7,750 units at $109.01) as part of a pre-agreed trading plan (SEC Form 4)
- Director Read Simon exercised 2,777 shares at a strike of $18.36 and sold $304,232 worth of shares (2,777 units at $109.55) as part of a pre-agreed trading plan (SEC Form 4)
- SVP, General Counsel and Sec. Veness Adam M sold $2,208,833 worth of shares (20,000 units at $110.44) as part of a pre-agreed trading plan and exercised 20,000 shares at a strike of $17.88 (SEC Form 4)
- SEC Form 144 filed by Dianthus Therapeutics Inc.
- Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors
- CEO AND PRESIDENT Garcia Marino exercised 166,000 shares at a strike of $8.44 and sold $17,945,451 worth of shares (166,000 units at $108.11) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Dianthus Therapeutics Inc.